Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Younes

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Journal of Hepatology|May 8, 2026
A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular CarcinomaDavid J Taggart, Shivani Mahajan, Maxime A Gallant, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Journal of Hepatology|May 8, 2026
A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular CarcinomaDavid J Taggart, Shivani Mahajan, Maxime A Gallant, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 9